• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    4/11/24 8:10:58 AM ET
    $ACOR
    $ALPN
    $APVO
    $BACK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Eliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million.
    • Rallybio (NASDAQ:RLYB) stock increased by 49.07% to $2.43. The company's market cap stands at $91.8 million.
    • Alpine Immune Sciences (NASDAQ:ALPN) shares rose 36.62% to $64.27. The company's market cap stands at $4.2 billion.
    • IMAC Hldgs (NASDAQ:BACK) stock increased by 22.41% to $3.44. The market value of their outstanding shares is at $3.9 million.
    • Healthcare Triangle (NASDAQ:HCTI) shares rose 15.3% to $1.77. The market value of their outstanding shares is at $8.2 million.
    • Lipocine (NASDAQ:LPCN) stock rose 15.2% to $7.5. The market value of their outstanding shares is at $39.8 million.

    Losers

    • Aptevo Therapeutics (NASDAQ:APVO) stock declined by 55.0% to $1.08 during Thursday's pre-market session.
    • SILO Pharma (NASDAQ:SILO) shares fell 13.34% to $1.82. The company's market cap stands at $5.1 million.
    • Acorda Therapeutics (NASDAQ:ACOR) shares decreased by 10.96% to $0.78.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares decreased by 10.25% to $1.84. The market value of their outstanding shares is at $2.4 million.
    • AVITA Medical (NASDAQ:RCEL) shares decreased by 9.98% to $13.0. The company's market cap stands at $334.1 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock declined by 9.79% to $0.44. The market value of their outstanding shares is at $1.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ALPN
    $APVO
    $BACK

    CompanyDatePrice TargetRatingAnalyst
    Avita Medical Inc.
    $RCEL
    11/20/2025Sell → Neutral
    BTIG Research
    Avita Medical Inc.
    $RCEL
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    Rallybio Corporation
    $RLYB
    4/9/2025Buy → Neutral
    H.C. Wainwright
    Avita Medical Inc.
    $RCEL
    12/24/2024$25.00Buy
    D. Boral Capital
    Rallybio Corporation
    $RLYB
    5/15/2024Overweight → Neutral
    JP Morgan
    Avita Medical Inc.
    $RCEL
    4/11/2024Buy → Neutral
    BTIG Research
    Alpine Immune Sciences Inc.
    $ALPN
    4/9/2024$55.00Buy
    Guggenheim
    Alpine Immune Sciences Inc.
    $ALPN
    2/15/2024$44.00Outperform
    Wolfe Research
    More analyst ratings

    $ACOR
    $ALPN
    $APVO
    $BACK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/29/22 4:34:43 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for TESTOSTERONE UNDECANOATE

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    12/20/20 4:30:41 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare Triangle Subsidiary QuantumNexis Inc. Launches its Dubai, UAE Operations to accelerate Digital Health Transformation across the GCC Countries

    The Dubai Operation strengthens Healthcare Triangle's mission to accelerate TeleHelath, Digital Therapeutics and population-scale care delivery across GCC.PLEASANTON, Calif., Feb. 27, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis Inc. has launched its Dubai, UAE operations in Meydan Free Zone to deliver clinically validated digital mental health solutions and AI powered Hospital Information System to the GCC markets. "This marks a major strategic expans

    2/27/26 7:18:00 AM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle Announces Approximately $3.959 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

    PLEASANTON, Calif., Feb. 26, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced today that it has entered into definitive agreements for the purchase and sale of 681,553 shares of common stock (or prefunded warrants in lieu thereof), par value $0.00001 per share, at a purchase price of $5.81 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 27, 2026, subject to the satisfaction of customary closing conditions. D. Boral Capital, LLC is acting as sole placement agent fo

    2/26/26 3:26:00 PM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle Subsidiary QuantumNexis and TNG Digital, the Operator of Malaysia's Leading Digital Financial Services and Lifestyle App, Announce Strategic Partnership to Provide Digital Mental Health Solutions to Its Over 25 Million Customers in Malaysia

    The partnership strengthens Healthcare Triangle's leadership at the intersection of digital health, fintech, and population-scale care delivery.PLEASANTON, Calif., Feb. 25, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis Malaysia Sdn Bhd (together with QuantumNexis, Inc. are hereafter referred to as "QuantumNexis") has entered a strategic partnership with TNG Digital, Malaysia's largest and most trusted digital payments and financial services platform, to

    2/25/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    $ACOR
    $ALPN
    $APVO
    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lieber Jonathan I sold $3,992 worth of shares (789 units at $5.06) and was granted 2,500 shares, increasing direct ownership by 71% to 4,115 units (SEC Form 4)

    4 - Rallybio Corp (0001739410) (Issuer)

    2/23/26 6:21:32 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO O'Toole David D bought $12,450 worth of shares (3,000 units at $4.15), increasing direct ownership by 2% to 140,127 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    2/23/26 4:30:08 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Mackay Martin

    4 - Rallybio Corp (0001739410) (Issuer)

    2/20/26 6:08:28 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    SEC Filings

    View All

    Healthcare Triangle Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    2/27/26 5:00:18 PM ET
    $HCTI
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by Rallybio Corporation

    SCHEDULE 13D/A - Rallybio Corp (0001739410) (Subject)

    2/27/26 4:45:52 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO O'Toole David D bought $12,450 worth of shares (3,000 units at $4.15), increasing direct ownership by 2% to 140,127 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    2/23/26 4:30:08 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ACOR
    $ALPN
    $APVO
    $BACK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avita Medical upgraded by BTIG Research

    BTIG Research upgraded Avita Medical from Sell to Neutral

    11/20/25 7:57:06 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical downgraded by BTIG Research with a new price target

    BTIG Research downgraded Avita Medical from Neutral to Sell and set a new price target of $3.00

    8/8/25 8:17:21 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces CEO Transition

    Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board. Mr. Vance will continue to serve as Chairman of the Board, while Board m

    10/16/25 6:15:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

    Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu

    8/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

    VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations

    1/13/26 8:25:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA® Medical Reports Third Quarter 2025 Financial Results

    VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the third quarter ended September 30, 2025. Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.Cash, cash equivalents, and marketable securities totaled $23.3 million as of Sept. 30, 2025.Operating expenses decreased by 24%, or $7.2 million, to $23.0 million, compared with $30.2 million in the corresponding period last year, as the Company continues to streamline operat

    11/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ALPN
    $APVO
    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

    SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/14/24 3:45:38 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care